|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Treatment of a Single Patient With CRD-TMH-001
The study is a single patient study intended to understand the effects of a gene-editing therapeutic to treat a rare mutation of Duchenne muscular dystrophy.
100 Clinical Results associated with Cure Rare Disease, Inc.
0 Patents (Medical) associated with Cure Rare Disease, Inc.
01 Oct 2023·Human gene therapy
Cure Rare Disease: An Initiative to Enable N of 1 Gene Editing.
Article
Author: Horgan, Richard W
100 Deals associated with Cure Rare Disease, Inc.
100 Translational Medicine associated with Cure Rare Disease, Inc.